However, the determination of the GTPase activity of the different KRAS mutants is not completed and conflicting results in a study performed in MCF10A breast cancer cells found that KRASG12D and KRASG13D mutants had similar GTPase activity to KRAS WT, but that KRASG12C and KRASG12V had higher GTP binding [7]. This evidence concerns the gene KRAS and breast carcinoma.